Standard treatments for autoimmune and autoinflammatory disorders rely mainly on immunosuppression. These are predominantly symptomatic remedies that do not affect the root cause of the disease and are associated with multiple side effects. Immunotherapies are being developed during the last decades as more specific and safer alternatives to small molecules with broad immunosuppressive activity, but they still do not distinguish between disease-causing and protective cell targets and thus, they still have considerable risks of increasing susceptibility to infections and/or malignancy. Antigen-specific approaches inducing immune tolerance represent an emerging trend carrying the potential to be curative without inducing broad immunosuppression. These therapies are based on antigenic epitopes derived from the same proteins that are targeted by the autoreactive T and B cells, and which are administered to patients together with precise instructions to induce regulatory responses capable to restore homeostasis. They are not personalized medicines, and they do not need to be. They are precision therapies exquisitely targeting the disease-causing cells that drive pathology in defined patient populations. Immune tolerance approaches are truly transformative options for people suffering from autoimmune diseases.

中文翻译：

---

新兴的自身免疫性疾病转化疗法大会议。

自身免疫和自身炎性疾病的标准治疗主要依靠免疫抑制。这些主要是对症治疗，不影响疾病的根本原因，并具有多种副作用。在过去的几十年中，免疫疗法正在发展成为具有广泛免疫抑制活性的小分子的更特异性和更安全的替代品，但它们仍无法区分引起疾病的靶标和具有保护作用的细胞，因此，它们仍然具有相当大的风险增加对感染和感染的敏感性。 /或恶性肿瘤。诱导免疫耐受的抗原特异性方法代表了一种新兴趋势，具有在不引起广泛免疫抑制的情况下具有治愈潜力。这些疗法基于抗原表位，该抗原表位衍生自自身反应性T细胞和B细胞所靶向的相同蛋白质，并与患者一起使用以精确指导指导患者恢复稳态。它们不是个性化药物，也不必如此。它们是精确地靶向致病细胞的精密疗法，这些致病细胞在确定的患者人群中推动了病理学。对于患有自身免疫性疾病的人来说，免疫耐受方法是真正的变革性选择。它们是精确地靶向致病细胞的精密疗法，这些致病细胞在确定的患者人群中推动了病理学。对于患有自身免疫性疾病的人来说，免疫耐受方法是真正的变革性选择。它们是精确地靶向致病细胞的精密疗法，这些致病细胞在确定的患者人群中推动了病理学。对于患有自身免疫性疾病的人来说，免疫耐受方法是真正的变革性选择。